TABLE 2.
Summary of case series of patients with infective endocarditis or treated with dalbavancina
| Reference | n | NV/PV/CD or IAI/BJI | Bacterium or bacteria (n)b,c | Most frequent dosing | Duration/no. of doses | Success, n (%)d | Adverse events (n) |
|---|---|---|---|---|---|---|---|
| Infective endocarditis | NV/PV/CD | ||||||
| Tobudic et al., 2018 (84) | 27 | 15/7/5 | S. aureus (9), CoNS (7), E. faecalis (4), other (9) | 1,500 mg LD then 1,000 mg every 2 wk or 1,000 mg LD then 500 mg weekly | Median, 6 wk (range, 1–30) | 25 (93) | Nausea (1), RCI (1) |
| Bouza et al., 2018 (85) | 7 | Not specifiede | S. aureus (1), CoNS (2), Enterococcus spp. (2), other (2)f | 1,000 mg LD then 500 mg weekly | Median, 3 doses (range, 1–24) | 6 (86) | Rash (2), tachycardia (2), RCI (2), nausea (1), rectal bleeding (1)g |
| Hidalgo-Tenorio et al., 2019 (86) | 34 | 11/15/8 | S. aureus (10), CoNS (15), E. faecalis (3), other (7) | 1,000 mg once or 1,500 mg LD then 500 mg at day 8 | Median, 14 days (IQR, 14–21) | 33 (97) | Fever (1), renal failure (1) |
| Bryson-Cahn et al., 2019 (87) | 9 | 9/−/− | S. aureus (9) | 1,000 mg once or 1,000–1,500 mg LD then 500 mg day 7 | 2 doses | 9 (100) | Not reported |
| Wunsch et al., 2019 (88) | 25 | 15/6/4 | Not specifiede | 1,000 mg LD then 500 mg weekly or 1,500 mg once or 1,500 mg weekly × 2g | Median, 3 doses (range, 1–32)g | 23 (92) | Dyspnea (1), hypertension during infusion (1), fatigue and vertigo (1)g |
| Dinh et al., 2019 (89) | 19 | 9/10/− | Not specifiede | 1,500 mg once or 1,500 mg LD then 1,000–1,500 mg at day 7 or 14 | 1–2 doses | 13 (68) | Hypersensitivity (2), headache (1), eosinophilia (1), phlebitis (1)g |
| Bork et al., 2019 (111) | 7 | Not specifiedh | Not specifiede | Not specifiede | Median, 4 doses | 4 (57) | Acute kidney injury (2), rash and pruritus (1)g |
| Veve et al., 2020 (112) | 12 | Not specifiede | Not specifiede | 1,500 mg once, 1,500 mg for 2 doses at day 1 and day 7, or 1,500 mg for 2 doses at day 1 and day 14 | 1–2 doses | NA (91)i | Catheter infection (1), hypersensitivity (1)g |
| Total | 140 | 59j/38/18 | 113j (88) | ||||
| Bone and joint infections | IAI/BJI | ||||||
| Rappo et al., 2019 (93) | 67 | −/67 | S. aureus (42), CoNS (14), Enterococcus (8), other (33)f | 1,500 mg weekly × 2 | 2 doses | 65 (97) | Drug-related treatment adverse event (1) |
| Bouza et al., 2018 (85) | 33 | 20/13 | S. aureus (9), CoNS (16), Enterococcus spp. (3), other (6)f | 1,000-mg LD then 500 mg weekly | Median, 3 doses (range, 1–24)g | 28 (85) | Rash (2), tachycardia (2), RCI (2), nausea (1), rectal bleeding (1), candidiasis (1)g |
| Morata et al., 2019 (95) | 64 | 45/19 | S. aureus (14), CoNS (33), Enterococcus spp. (9), other (22)f | 1,000-mg LD then 500 mg weekly | Median, 5 doses | 45 (70) | GI problems (3), rash (1), phlebitis (1), asthenia (1), RCI (1) |
| Almangour et al., 2019 (96) | 31 | −/31 | S. aureus (27), CoNS (1), other (6)f | 1,000 mg LD then 500 mg weekly or 1,500 mg weekly × 2 | Median, 3 doses | 28 (90) | None |
| Tobudic et al., 2019 (97) | 46 | 8/38 | Not specifiedk | 1,500 mg LD then 1,000 mg every 2 wk, 1,000 mg LD then 500 mg weekly, or 1,500 mg LD then 1,500 mg at day 8g | Range, 2–32 dosesl | 30 (65) | Nausea (1), exanthema (2), hyperglycemia (1)g |
| Dinh et al., 2019 (89) | 48 | −/48 | Not specifiedk | 1,500 mg every 7–14 days × 2 or 1,500 mg once | Range, 1–10 doses | 35 (73) | Hypersensitivity (2), headache (1), eosinophilia (1), phlebitis (1)g |
| Wunsch et al., 2019 (88) | 62 | 32/30 | Not specifiedk | 1,000 mg LD then 500 mg weekly, 1,500 mg once, or 1,500 mg weekly × 2g | Median, 3 doses (range, 1–32)g | 58 (94) | Dyspnea (1), hypertension (1), fatigue and vertigo (1)g |
| Matt et al., 2021 (98) | 17 | 17/− | S. aureus (10), CoNS (10), E. faecalis (1), other (5)f | 1,500 mg weekly × 2 or 1,500 mg once | Median, 2 doses (range, 1–10)g | 8 (47) | None |
| Buzón-Martín et al., 2019 (99) | 16 | 16/− | S. aureus (6), CoNS (7), Enterococcus spp. (6) | 1,500 mg LD, then 500 mg on day 7, then 500 mg every 2 wk | Range, 6–12 wk | 11 (69) | Leukopenia (1), rash (1) |
| Bork et al., 2019 (111) | 15 | Not specified | Not specifiede | Not specifiede | Median, 4 doses | 7 (47) | Acute kidney injury (2), rash and pruritus (1)g |
| Veve et al., 2020 (112) | 49 | Not specified | Not specifiedk | 1,500 mg once, 1,500 mg for 2 doses at day 1 and day 7, or 1,500 mg for 2 doses at day 1 and day 14 | 1–2 doses | NA (91)i | Catheter infection (1), hypersensitivity (1)g |
| Cojutti et al., 2021 (94) | 15 | 11/4 | S. aureus (5), CoNS (9), E. faecalis (1) | 1,500 mg weekly × 2 | 2 doses | 12 (80) | None |
| Total | 463 | 149/250j | 327j (79) | ||||
BJI, bone and joint infection without implant (e.g., vertebral osteomyelitis, septic arthritis); CD, cardiac device; CoNS, coagulase-negative staphylococci; GI, gastrointestinal; IAI, implant-associated infection (e.g., prosthetic joint infection); LD, loading dose; NV, native valve; PV, prosthetic valve; RCI, reversible creatinine increase.
Includes methicillin-susceptible and -resistant S. aureus.
Categories are not mutually exclusive; polymicrobial cultures are included.
Definitions of clinical success were heterogeneous across the studies. For details, refer to individual publication.
Not specified for infective endocarditis.
“Other” also includes sterile cultures or unavailable cultures.
Corresponds to total cohort for those studies that reviewed cases with different infection sources.
One patient had a cardiac device infection; the other 6 patients had an unspecified endovascular infection that excluded bacteremia.
Clinical success rate for entire cohort, not specified for infective endocarditis or bone and joint infections.
Excludes studies where clinical outcomes were not specified for infective endocarditis or bone and joint infections.
Not specified for IAI and BJI.
Osteomyelitis median of 8 weeks (range, 4 to 32 weeks), vertebral osteomyelitis median of 9 weeks (range, 2 to 16 weeks), acute septic arthritis median of 3.5 weeks (range, 2 to 10 weeks), and prosthetic joint infection median of 12 weeks (range, 6 to 32 weeks).